Stanford Radiology provides patient-centric imaging services using state-of-the-art technology at each of five distinct imaging locations. These include Stanford Medicine Imaging Center, Palo Alto; Stanford Medicine Outpatient Center, Redwood City; Blake Wilbur Outpatient Clinic; Stanford Hospital Department of Radiology; and Stanford Advanced Medicine Center/Cancer Center. Innovative approaches to the design of the physical facilities, always with the patient's experience in mind, have led to improvements garnering the highest in patient-satisfaction ratings. These improvements have included the addition of specialized staffing, and expedited scheduling, insurance approvals, and report turnaround times. To ensure that our patients receive the highest standard of care, our specialized staffing includes, for example, the CT protocol technologist, whose main responsibility is to lower, standardize, and monitor CT dose at all of our CT scanner locations. In FY 2011, and continuing into 2012, we are engaged in the testing of new methods to improve the patient experience by studying the impact of radiologist-patient communication on patient care. These types of studies are part of our over-arching goal to advance personalized medicine, and increase the interaction between radiologists and their patients.
Clinical Trials conducted by investigators from Radiology foster study of both drug and device interventions, as well as other issues. Device and interventional studies include those to correct carotid stenosis, thrombus removal, stent placements, and high intensity focused ultrasound (HIFU) studies. Some of the drug intervention trials study the combining of drugs with other treatment modalities, evaluating drug effectiveness with multiple imaging modalities, differentiating cancer from infection using drug-enhanced imaging, combining chemoembolization with drugs in cancer treatment for unresectable cancer, characterizing cancer lesions with drug-enhanced ultrasound imaging, investigating tumor accumulation of drugs, quantifying collateral perfusion in cerebrovascular disease and stroke patients, as well as studying the biodistribution and safety of imaging probes. Device intervention trials include study of the SoftScan optical breast imaging system, and use of TheraSphere in unresectable hepatocellular carcinoma.